How Employer-Sponsored High-Deductible Health Plans Are Handling the 2026 Launch of Ocrevus ZUNOVO and Its PBM Rebate Classification Shift
As of early 2026, employer-sponsored high-deductible health plans (HDHPs) are scrambling to update specialty drug coverage ahead of the commercial rollout of Ocrevus ZUNOVO. This new subcutaneous formulation of ocrelizumab from Genentech (a Roche company) is poised to replace a large share of the old infusion-only Ocrevus claims. The move affects not only employees living with relapsing and primary progressive multiple sclerosis but also the way pharmacy benefit managers (PBMs) handle and rebate this expensive therapy. A small drug launch on paper, but a big deal in plan budgets.
Ocrevus ZUNOVO and Why Its Classification Matters
Genentech earned FDA approval for Ocrevus ZUNOVO in late 2025 as a mix of ocrelizumab and hyaluronidase for subcutaneous injection. The new version cuts administration time dramatically compared with the original intravenous infusion, which has always been billed on the medical side. Now, with pharmacy dispensing in the mix, employers have to decide: keep it under the medical benefit or move it to pharmacy benefit adjudication. It sounds bureaucratic, but that decision determines who manages pricing , and who pockets the rebate.
Rebate implications are immediate. Traditionally, PBMs negotiate larger rebates for drugs processed under the pharmacy benefit than under medical benefit billing. But CMS transparency rules taking effect in 2025 changed how rebate dollars are reported and split between PBMs and plan sponsors. In response, some PBMs have started labeling drugs like Ocrevus ZUNOVO as “non-rebatable” if they fall under IRA inflation caps or fail to meet internal rebate-value thresholds. Translation: less back-end money flowing to employers and more emphasis on net price at the point of sale.
HDHPs Adjusting to the New Price Transparency and Rebate Reality
Employer HDHPs face a double bind. They have to price a new specialty therapy that costs roughly $65,000 per year while also a rebate model that no longer guarantees offset income. Since IRS rules still require members in HSA-qualified HDHPs to hit their deductible before most drug costs count, employers are weighing whether Ocrevus ZUNOVO deserves a preventive exception under Notice 2019-45. A few consulting firms are already encouraging clients to test that angle for chronic MS maintenance.
According to the PBMI 2025 Employer Benchmark Report, 71% of large employers use rebate guarantees to control specialty costs, but only 14% of HDHP sponsors pass rebates back to employees. Once Ocrevus ZUNOVO drops off the rebate list, those offset dollars shrink. For plans tied to PBMs with performance-based specialty contracts, that means lower rebate revenue and fewer administrative fee credits. On the bright side, list-to-net spread is expected to narrow, which can mean more predictable cash flow for employers who hated the old rebate guessing game anyway.
Comparison: Ocrevus IV vs. Ocrevus ZUNOVO Under Employer HDHP Models
| Feature | Ocrevus (IV Infusion) | Ocrevus ZUNOVO (Subcutaneous) |
|---|---|---|
| Manufacturer | Genentech (Roche) | Genentech (Roche) |
| Route of Administration | Intravenous infusion at an infusion center | Subcutaneous injection (clinic or specialty pharmacy) |
| Typical Benefit Category | Medical benefit | Pharmacy or medical benefit, depending on plan |
| List Price (2026 WAC) | Approximately $66,000 annually | Approximately $67,500 annually |
| PBM Rebate Classification | Eligible for standard specialty rebate rates (pre-2025 contracts) | Non-rebatable or inflation-adjusted category under 2026 PBM models |
| Member Cost Exposure (HDHP pre-deductible) | Limited until claim hits deductible on medical side | Full drug cost accrues to deductible unless preventive exception applies |
| Administration Cost | Facility and nursing fees billed separately | No facility fee; potential dispensing or injection fee |
Formulary Placement and Out-of-Pocket Impact in 2026
Ocrevus IV usually runs through specialty medical management programs with 20%-30% coinsurance post-deductible. For 2026, PBM filings show ZUNOVO landing anywhere from Tier 4 (preferred specialty) to Tier 6 (non-preferred), depending on contract performance metrics. CVS Health and OptumRx each hinted at Tier 4 placement tied to value-based outcomes deals. For employees, that means potential yearly out-of-pocket charges between $2,000 and $7,000 depending on deductible size and whether the employer uses accumulator caps. A wide range , and sometimes a painful one early in the year.
Unlike the infusion model, pharmacy-processed ZUNOVO charges members up front at the pharmacy counter. It’s transparent, yes, but that clarity can backfire for adherence. A $3,000 January refill bill can scare even the most compliant patient. Some benefits teams are looking to carve out a preventive exception midyear for clinically stable MS members so treatment continuity isn’t at the mercy of one deductible reset. A pragmatic approach, even if paperwork-heavy.
PBM and Employer Contract Adjustments in Motion
The 2026 PBM renewal cycle confirms what most analysts suspected: rebate-free “net cost” contracts are taking over. Many PBMs are carving out Ocrevus ZUNOVO from rebate pools entirely while anchoring price protections to average manufacturer net pricing. In the 2026 Kaiser Family Foundation Employer Health Benefits Survey, about 38% of large groups said they’ve moved to these transparency-first contracts that curb spread pricing and eliminate rebate holdbacks. It’s cleaner accounting but less wiggle room for wellness funding or vendor incentives built on rebate share.
HDHP sponsors depending on rebate income for premium stabilization are especially exposed. One Midwest employer told PBMI it lost $180,000 in rebate credits in 2026 after its PBM reclassified ZUNOVO as non-rebatable. The company raised non-preferred coinsurance caps by 5% to cover the gap. That’s becoming the new norm , shifting costs carefully, not dramatically, while waiting to see which PBM model actually holds up under CMS audits.
What Patients, Pharmacists, and Benefits Teams Should Expect
Pharmacists will see heavier prior authorization workloads, verifying MS subtype, confirming previous IV use, and coordinating delivery. Patients get shorter infusion times and simplified access but higher point-of-sale costs under HDHP design. The trade-off is speed: pharmacy claims move faster than medical buy-and-bill, and approvals often post in days instead of weeks. Whether that convenience outweighs the sticker shock is anyone’s guess.
For employers, 2026 will test whether point-of-sale transparency and non-rebatable drug designations can realistically coexist with affordability programs. Copay assistance handling remains a headache since CMS clarified in 2026 filings that manufacturer-funded amounts don’t count toward deductibles. That rule will sting for anyone expecting assistance to help bridge the early-year HDHP gap.
HDHPs have always been a balancing act , lower premiums traded for higher immediate exposure. The Ocrevus ZUNOVO rollout just makes that trade more visible. And honestly, that visibility might finally force some employers to reassess whether rebate logic is dictating too much of their health plan design.
Disclaimer: This article provides general informational analysis on employer health plan coverage and PBM contracting. It does not constitute legal, medical, or financial advice. Patients should consult their physician and plan administrator for individualized guidance.